Vanguard Capital Management
CRDF icon

Vanguard Capital Management’s Cardiff Oncology CRDF Stock Holding History

Vanguard Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.76M Buy
2,895,592
+39,626
+1% +$62.9K ﹤0.01% 3216
2026
Q1 		$4.63M Buy
+2,855,966
New +$5.87M ﹤0.01% 3092

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management's CRDF Position: Q2 2026 in Review

Vanguard Capital Management increased its Cardiff Oncology (CRDF) stake by 1.4% in Q2 2026, buying an estimated $62.9K and bringing the position to 2,895,592 shares worth $3.76M. The position accounts for ﹤0.01% of the portfolio, ranked #3216.

Vanguard Capital Management first reported a position in CRDF in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.63M in Q1 2026. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Vanguard Capital Management held 2,895,592 shares of Cardiff Oncology worth $3.76M as of Q2 2026.
  • Vanguard Capital Management bought 39,626 Cardiff Oncology shares in Q2 2026, an estimated $62.9K.
  • Cardiff Oncology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3216 holding.
  • Vanguard Capital Management first reported a position in Cardiff Oncology in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Cardiff Oncology position peaked at $4.63M in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.